Zimbabwe has turned down a major US healthcare agreement valued at $367m (272 million pounds) over five years over the United States' insistence on sensitive biological samples.
The decision was revealed after a official document dated December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "lopsided".
An official representative later stated that the US was demanding access to genetic material for research and commercial purposes but was not willing to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for more dialogue to secure a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the security of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
As per statements, Sixteen African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our population if a future disease outbreak arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending frameworks already established through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This system is intended to guarantee that when a nation provides its samples, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how subsequent collaboration might be structured in a manner that honours the independence and interests of both nations."
Medical Community Response
Medical experts said it recognised the government's concerns, but suggested that talks should continue given that much of the nation's HIV programmes relied on foreign aid.
"Where technical issues exist, including those involving information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," the group added.
The halted deal emphasises the complex challenges between accepting crucial international aid and protecting local interests in an ever more interconnected world.